{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:59:19Z","timestamp":1777651159383,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1124\/mol.117.108381","type":"journal-article","created":{"date-parts":[[2017,8,26]],"date-time":"2017-08-26T00:25:48Z","timestamp":1503707148000},"page":"502-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis"],"prefix":"10.1016","volume":"92","author":[{"given":"Hisashi","family":"Wakita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Kuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/mol.117.108381_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-61779-909-9_9","article-title":"\u03b2-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation","volume":"897","author":"Bassoni","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1124\/mol.117.108381_bib2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/mol.117.108381_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/385640a0","article-title":"A new class of membrane-bound chemokine with a CX3C motif","volume":"385","author":"Bazan","year":"1997","journal-title":"Nature"},{"key":"10.1124\/mol.117.108381_bib4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1189\/jlb.0408231","article-title":"The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice","volume":"84","author":"Bento","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1124\/mol.117.108381_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1572-0241.2005.00361.x","article-title":"Increased expression of the chemokine fractalkine in Crohn\u2019s disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype","volume":"101","author":"Brand","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/mol.117.108381_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.117.108381_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","article-title":"Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion","volume":"91","author":"Imai","year":"1997","journal-title":"Cell"},{"key":"10.1124\/mol.117.108381_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2144\/000113496","article-title":"Novel mouse model of colitis characterized by hapten-protein visualization","volume":"49","author":"Ishiguro","year":"2010","journal-title":"Biotechniques"},{"key":"10.1124\/mol.117.108381_bib9","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1073\/pnas.1114931109","article-title":"Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis","volume":"109","author":"Kayama","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.117.108381_bib10","doi-asserted-by":"crossref","first-page":"G803","DOI":"10.1152\/ajpgi.00069.2006","article-title":"Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells","volume":"291","author":"Khan","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/mol.117.108381_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ibd.20113","article-title":"Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes","volume":"13","author":"Kobayashi","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1124\/mol.117.108381_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1254\/jphs.FP0040214","article-title":"Oxazolone-induced colitis in BALB\/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis","volume":"96","author":"Kojima","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/mol.117.108381_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1189\/jlb.1109768","article-title":"Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice","volume":"88","author":"Kostadinova","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1124\/mol.117.108381_bib14","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1172\/JCI59150","article-title":"CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice","volume":"121","author":"Medina-Contreras","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.117.108381_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jdermsci.2016.03.004","article-title":"CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages","volume":"82","author":"Morimura","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1124\/mol.117.108381_bib16","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.4049\/jimmunol.0901936","article-title":"Enteric flora expands gut lamina propria CX3CR1+ dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions","volume":"184","author":"Niess","year":"2010","journal-title":"J Immunol"},{"key":"10.1124\/mol.117.108381_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1749-6632.2009.04738.x","article-title":"Chemokines as novel therapeutic targets for inflammatory bowel disease","volume":"1173","author":"Nishimura","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/mol.117.108381_bib18","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.168.12.6173","article-title":"Dual functions of fractalkine\/CX3C ligand 1 in trafficking of perforin+\/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression","volume":"168","author":"Nishimura","year":"2002","journal-title":"J Immunol"},{"key":"10.1124\/mol.117.108381_bib19","doi-asserted-by":"crossref","first-page":"G135","DOI":"10.1152\/ajpgi.90462.2008","article-title":"T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade","volume":"296","author":"Ostanin","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/mol.117.108381_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2006.10.010","article-title":"Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease","volume":"132","author":"Sans","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1124\/mol.117.108381_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","article-title":"Targeting leukocyte migration and adhesion in Crohn\u2019s disease and ulcerative colitis","volume":"20","author":"Thomas","year":"2012","journal-title":"Inflammopharmacology"},{"key":"10.1124\/mol.117.108381_bib22","unstructured":"Yoshida I, Okabe T, Matsumoto Y, Watanabe N, Ohashi Y, Onizawa Y, and Harada H (2013) inventors, Eisai R&D Management Co., Ltd., assignee. Pyrrolidin-3-ylacetic acid derivative. U.S. patent 8476301. 2013 Jul 2."},{"key":"10.1124\/mol.117.108381_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0065-2776(01)78002-9","article-title":"Chemokines in immunity","volume":"78","author":"Yoshie","year":"2001","journal-title":"Adv Immunol"},{"key":"10.1124\/mol.117.108381_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/1087057108321531","article-title":"A homogeneous enzyme fragment complementation-based \u03b2-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors","volume":"13","author":"Zhao","year":"2008","journal-title":"J Biomol Screen"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2400645X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2400645X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.117.108381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:20:37Z","timestamp":1739960437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X2400645X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0026895X2400645X"],"URL":"https:\/\/doi.org\/10.1124\/mol.117.108381","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.117.108381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}